GlobeNewswire: Novozymes A/S Contains the last 10 of 1668 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:06:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/21/2849915/0/en/2024-outlook-and-pro-forma-financials.html?f=22&fvtc=4&fvtv=85802024 outlook and pro forma financials2024-03-21T06:26:23Z<![CDATA[Novonesis provides outlook for 2024 with expected 5-7% organic sales growth and ~35% adj. EBITDA margin. Pro forma financials disclosed.]]>https://www.globenewswire.com/news-release/2024/03/18/2847937/0/en/Novonesis-will-host-a-conference-call-regarding-2024-outlook-and-2023-pro-forma-financials-on-March-21.html?f=22&fvtc=4&fvtv=8580Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 212024-03-18T14:26:29Z<![CDATA[Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 at 9.00am CET.]]>https://www.globenewswire.com/news-release/2024/03/04/2839800/0/en/Resolutions-from-the-Extraordinary-Shareholders-Meeting-2024.html?f=22&fvtc=4&fvtv=8580Resolutions from the Extraordinary Shareholders’ Meeting 20242024-03-04T16:06:25Z<![CDATA[]]>https://www.globenewswire.com/news-release/2024/02/09/2826627/0/en/Invitation-to-an-extraordinary-shareholders-meeting-of-Novozymes-A-S.html?f=22&fvtc=4&fvtv=8580Invitation to an extraordinary shareholders’ meeting of Novozymes A/S2024-02-09T09:00:00Z<![CDATA[An extraordinary shareholders’ meeting of Novozymes A/S will be held on Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark.]]>https://www.globenewswire.com/news-release/2024/02/08/2826390/0/en/The-Novozymes-Report-2023.html?f=22&fvtc=4&fvtv=8580The Novozymes Report 20232024-02-08T18:52:20Z<![CDATA[This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024.]]>https://www.globenewswire.com/news-release/2024/02/02/2822832/0/en/Trading-by-management-and-close-relations-of-management.html?f=22&fvtc=4&fvtv=8580Trading by management and close relations of management2024-02-02T13:13:28Z<![CDATA[]]>https://www.globenewswire.com/news-release/2024/02/02/2822617/0/en/Settlement-of-the-combination-of-Novozymes-and-Chr-Hansen-Holding-successfully-completed.html?f=22&fvtc=4&fvtv=8580Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed2024-02-02T07:28:31Z<![CDATA[]]>https://www.globenewswire.com/news-release/2024/02/01/2821694/0/en/Legacy-Novozymes-delivers-solid-last-full-year-results.html?f=22&fvtc=4&fvtv=8580Legacy Novozymes delivers solid last full-year results 2024-02-01T07:00:39Z<![CDATA[Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality.]]>https://www.globenewswire.com/news-release/2024/02/01/2821675/0/en/Results-update-for-2023-unaudited.html?f=22&fvtc=4&fvtv=8580Results update for 2023 – unaudited2024-02-01T06:59:37Z<![CDATA[6% organic sales growth in Q4 and 5% for the full year with solid margins and free cash flow generation]]>https://www.globenewswire.com/news-release/2024/01/31/2821117/0/en/Total-number-of-voting-rights-and-capital-on-January-31-2024.html?f=22&fvtc=4&fvtv=8580Total number of voting rights and capital on January 31, 20242024-01-31T13:20:46Z<![CDATA[]]>